1 “... shorter for those patients who lose weight prior to starting cancer treatment. Maintaining a healthy diet...”

2 “... shorter for those patients who lose weight prior to starting cancer treatment. Maintaining a healthy diet...”

3 “... illness phases. Many patients enter treatment with weight loss and up to 80% lose additional weight during...”

4 “... illness phases. Many patients enter treatment with weight loss and up to 80% lose additional weight during...”

5

6 “... noted. Thus, this update will expand on the work of the previous CADTH reports to further investigate...”

7 “... noted. Thus, this update will expand on the work of the previous CADTH reports to further investigate...”

8 “... component. The CADTH clinical review also noted uncertainty in the meaningfulness of the observed...”

9 “..., such as the sudden death of a loved one, a serious accident, a natural disaster, sexual or physical assault...”

10 “.... Of note, the Canadian Drug Expert Committee recommendations for the existing DPP-4 inhibitors have...”

11 “.... Of note, the Canadian Drug Expert Committee recommendations for the existing DPP-4 inhibitors have...”

12 “...). As the Canadian Biosafety Standards and Guidelines note: "Using the wrong respirator or misusing one can...”

13 “... of individual P2Y12 inhibitors. Of note, the patient subgroups were selected based on the clinical components...”

14 “.... Rituximab was given a positive recommendation, however the Committee noted that the evidence for repeated...”

15 “... of individual P2Y12 inhibitors. Of note, the patient subgroups were selected based on the clinical components...”

16 “.... Rituximab was given a positive recommendation, however the Committee noted that the evidence for repeated...”

17 “... is ongoing about the optimal duration of DAPT. Of note, patient characteristics may be an important factor...”

18 “... is ongoing about the optimal duration of DAPT. Of note, patient characteristics may be an important factor...”

19 “... at a WTP threshold of $50,000 per QALY. It should be noted there is significant uncertainty around...”

20 “... criteria be modified to reflect the indication under review. Of note, Canadian Expert Drug Advisory...”